SESSION TITLE: COPD Treatment Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: Exacerbations of chronic obstructive pulmonary disease (COPD) cause morbidity, hospital admissions, and mortality, and strongly influence health-related quality of life (HRQL). We conducted a study in order to identify most common bacterial agents involved in COPD exacerbations, to assess severity of exacerbations using Anthonisen criteria and also to evaluate HRQL during and after COPD exacerbations using COPD Assesment Test (CAT).
METHODS: We evaluate 174 patients with exacerbations of COPD , (99 men, mean age 58±18, 75 women, mean age 62±16), admitted in our department during January 2010 to December 2012; From all patients, 21% were ex-smokers, 23% were nonsmokers and 56% were active smokers with a cumulative consumption > 10 pack-years. All patients were clinical examined and were performed both sputum culture and lung function tests.
RESULTS: In 62/174 patients (35.63%) sputum culture was positive for following pathogenic microorganisms: Haemophilus influenzae - 28.2%, S pneumoniae - 24.12%, Moraxella - 16.2%, Pseudomonas Aeruginosa -13.2%, Enterobacter spp.-8.12%, Klebsiella spp. - 6.3%, Acinetobacter spp.- 2.12%, E coli - 1.74%. In according to Anthonisen criteria, exacerbations were qualified as mild in 35/174 (20.11%) cases, moderate in 77/174 (44.25%) cases and severe in 62/174 (35.63%) cases. There was a significant statistic corelation (p<0.001) for HRQL using CAT before and after COPD exacerbation, with improvement of HRQL after COPD exacerbation.
CONCLUSIONS: In conclusion, most frequent microorganisms involved in acute exacerbations of COPD were H influenzae, S pneumoniae and Moraxella. The majority of hospitalized patients were classified in moderate and severe grade of exacerbations, also HRQL of patients was improved after COPD exacerbation treatment.
CLINICAL IMPLICATIONS: COPD infectious exacerbations requiring active prevention, early recognition and treatment to increase the quality of life of the patients with COPD.
DISCLOSURE: The following authors have nothing to disclose: Doina-Adina Todea, Paraschiva Postolache, Andreea-Cristina Herescu, Loredana-Elena Rosca, Andreea-Codruta Coman
No Product/Research Disclosure Information